GEN Exclusives

More »

GEN News Highlights

More »
Jan 12, 2009

Illumina Invests $18M in Oxford Nanopore’s Sequencing Platform

  • Illumina and Oxford Nanopore entered an alliance covering Oxford Nanopore’s BASE™ Technology products for DNA sequencing. Illumina made an equity investment of $18 million, which will be used to accelerate the development of this platform. Illumina also agreed to make an additional equity investment upon the achievement of a specific technical milestone.

    Additionally, Illumina will exclusively market, sell, distribute, and service BASE™ Technology products to the research and diagnostic markets on a worldwide basis. Illumina and Oxford Nanopore will share profits generated from sales.

    Oxford Nanopore’s sequencing system uses protein nanopores coupled with a processive enzyme. This system is designed for direct electrical identification of DNA bases at the single-molecule level without the need for fluorescent labels.

    “Oxford Nanopore’s technology holds tremendous promise to achieve the sub-$1,000 human genome,” notes Jay Flatley, President and CEO of Illumina. “Making electrical measurements of unmodified DNA removes the need for complex sample prep and the high-performance optics found in today’s sequencing systems.”
     
    ---

     



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?